Azeliragon

Investigational drug for Alzheimer's disease

Azeliragon
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Azeliragon is an investigational drug that was being developed for the treatment of Alzheimer's disease. It is a small molecule antagonist of the receptor for advanced glycation end-products (RAGE). The drug was initially developed by Pfizer and later by vTv Therapeutics.

Mechanism of Action

Azeliragon works by inhibiting the interaction between RAGE and its ligands. RAGE is a multi-ligand receptor of the immunoglobulin superfamily, and its activation is implicated in various pathological processes, including inflammation and neurodegeneration. In Alzheimer's disease, the accumulation of advanced glycation end-products (AGEs) and amyloid-beta peptides can activate RAGE, leading to oxidative stress and inflammation, which contribute to the progression of the disease. By blocking RAGE, azeliragon aims to reduce these pathological processes.

Development History

Azeliragon was originally discovered by Pfizer and was known as PF-04494700. It was later licensed to vTv Therapeutics, which continued its development. The drug underwent several clinical trials to assess its safety and efficacy in patients with mild to moderate Alzheimer's disease.

Clinical Trials

Azeliragon was evaluated in multiple clinical trials. Early phase studies suggested potential benefits in slowing cognitive decline. However, subsequent larger trials did not demonstrate significant efficacy, leading to the discontinuation of its development for Alzheimer's disease.

Pharmacokinetics

Azeliragon is administered orally. It is absorbed into the bloodstream and crosses the blood-brain barrier, allowing it to exert its effects within the central nervous system. The pharmacokinetic profile of azeliragon includes its absorption, distribution, metabolism, and excretion, which were studied during its clinical development.

Potential Side Effects

As with many investigational drugs, azeliragon was associated with certain side effects during clinical trials. Commonly reported adverse effects included headache, dizziness, and gastrointestinal disturbances. The safety profile was considered acceptable in early trials, but the lack of efficacy led to the cessation of its development.

Current Status

As of the latest updates, azeliragon is no longer being actively developed for Alzheimer's disease. The challenges in demonstrating significant clinical benefits in large-scale trials have led to a shift in focus towards other therapeutic targets and strategies in Alzheimer's research.

Related Pages

• Alzheimer's disease
• Receptor for advanced glycation end-products
• Amyloid-beta
• Neurodegeneration